Form 4: Anixa Biosciences Director Acquires 25,000 Stock Options
SEC Form 4 Filing
Director Arnold M. Baskies acquired 25,000 employee stock options in Anixa Biosciences Inc. on January 2, 2025, according to a Form 4 filing.
Summary
- On January 2, 2025, Arnold M. Baskies, a director of Anixa Biosciences Inc., acquired 25,000 employee stock options.
- The options were granted under the company's 2018 Share Incentive Plan.
- The exercise price of the options is $2.37.
- The options vest in twelve equal monthly installments beginning January 31, 2025, and expire on January 2, 2035.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.
Industry Context
This is a standard disclosure of insider activity. Option grants are a common form of executive compensation in the biotechnology industry.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of transaction: Arnold M. Baskies acquired 25,000 employee stock options. |
| 01/31/2025 | Options vest and become exercisable in twelve equal monthly installments beginning this date. |
| 01/03/2025 | Date of signature on the Form 4 filing. |
| 01/02/2035 | Expiration date of the employee stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.